Exact Sciences Corporation $EXAS Shares Sold by EULAV Asset Management

EULAV Asset Management cut its holdings in Exact Sciences Corporation (NASDAQ:EXAS) by 6.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 266,000 shares of the medical research company’s stock after selling 17,000 shares during the quarter. EULAV Asset Management’s holdings in Exact Sciences were worth $14,553,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of EXAS. Great Lakes Advisors LLC grew its holdings in Exact Sciences by 3.7% during the 1st quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company’s stock valued at $215,000 after buying an additional 178 shares during the last quarter. Capital Asset Advisory Services LLC raised its holdings in shares of Exact Sciences by 4.8% in the third quarter. Capital Asset Advisory Services LLC now owns 3,941 shares of the medical research company’s stock worth $216,000 after acquiring an additional 182 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its position in shares of Exact Sciences by 0.4% in the second quarter. DekaBank Deutsche Girozentrale now owns 58,333 shares of the medical research company’s stock valued at $3,127,000 after acquiring an additional 217 shares in the last quarter. IFP Advisors Inc boosted its stake in shares of Exact Sciences by 6.5% during the second quarter. IFP Advisors Inc now owns 4,466 shares of the medical research company’s stock valued at $237,000 after acquiring an additional 273 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its position in Exact Sciences by 37.0% during the 2nd quarter. Farther Finance Advisors LLC now owns 1,018 shares of the medical research company’s stock worth $54,000 after purchasing an additional 275 shares in the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Insider Activity

In other news, EVP Brian Baranick sold 2,858 shares of the firm’s stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $70.08, for a total value of $200,288.64. Following the transaction, the executive vice president directly owned 22,368 shares in the company, valued at $1,567,549.44. This trade represents a 11.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Jacob A. Orville sold 5,000 shares of Exact Sciences stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price of $75.00, for a total value of $375,000.00. Following the completion of the transaction, the executive vice president directly owned 23,237 shares in the company, valued at $1,742,775. This represents a 17.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 1.20% of the company’s stock.

Exact Sciences Stock Performance

NASDAQ:EXAS opened at $102.34 on Friday. The company has a market cap of $19.53 billion, a P/E ratio of -19.24, a P/E/G ratio of 2.41 and a beta of 1.40. The firm’s 50 day moving average is $95.79 and its two-hundred day moving average is $68.16. Exact Sciences Corporation has a fifty-two week low of $38.81 and a fifty-two week high of $102.66. The company has a quick ratio of 2.44, a current ratio of 2.72 and a debt-to-equity ratio of 0.93.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.11. The business had revenue of $850.74 million during the quarter, compared to the consensus estimate of $810.42 million. Exact Sciences had a positive return on equity of 1.67% and a negative net margin of 32.01%.The business’s revenue for the quarter was up 20.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.21) EPS. Analysts expect that Exact Sciences Corporation will post -0.58 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Benchmark lowered shares of Exact Sciences from a “buy” rating to a “hold” rating in a report on Monday, November 24th. Evercore ISI set a $105.00 price objective on shares of Exact Sciences and gave the company an “in-line” rating in a research note on Monday, January 5th. Wall Street Zen lowered shares of Exact Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Barclays reiterated an “equal weight” rating and issued a $105.00 price target (up from $77.00) on shares of Exact Sciences in a report on Thursday, November 20th. Finally, Wells Fargo & Company restated an “equal weight” rating and set a $105.00 price objective (up previously from $85.00) on shares of Exact Sciences in a report on Thursday, November 20th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, twenty have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $87.06.

Exact Sciences Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.